Tasquinimod

TargetMol
Product Code: TAR-T6695
Supplier: TargetMol
CodeSizePrice
TAR-T6695-1mg1mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-2mg2mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-1mL1 mL * 10 mM (in DMSO)£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-10mg10mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-25mg25mg£255.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-50mg50mg£344.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-100mg100mg£488.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6695-500mg500mg£1,002.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Tasquinimod is a quinoline-3-carboxamide linomide analog with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
CAS:
254964-60-8
Formula:
C20H17F3N2O4
Molecular Weight:
406.361
Pathway:
Chromatin/Epigenetic; DNA Damage/DNA Repair
Purity:
0.995
SMILES:
COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12
Target:
HDAC

References

Isaacs JT, et al. Cancer Res.2013, 73(4), 1386-1399. Raymond E, et al. Cancer Chemother Pharmacol.2014, 73(1), 1-8. Isaacs JT, et al. Prostate.2006, 66(16), 1768-1778.